HomeTagsAbbVie

AbbVie

Biotechnology

The Lancet Publishes Results from Phase 3 Induction

PR Newswire - May 31, 2022

AbbVie announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (RINVOQ)...

Biotechnology

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

PR Newswire - January 17, 2022

AbbVie announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults...

1 23Page 3 of 3